Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus.

Creative Commons License

Philis-Tsimikas A., Astamirova K., Gupta Y., Haggag A., Roula D., Bak B. A., ...More

Diabetes research and clinical practice, vol.147, pp.157-165, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 147
  • Publication Date: 2019
  • Doi Number: 10.1016/j.diabres.2018.10.024
  • Journal Name: Diabetes research and clinical practice
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.157-165
  • Keywords: IDegAsp, Glargine, Aspart, Diabetes, Co-formulation, Hypoglycaemia, ASSOCIATION, MANAGEMENT, DEGLUDEC, IMPACT
  • Dokuz Eylül University Affiliated: Yes


Aims: To confirm non-inferiority of insulin degludec/insulin aspart (IDegAsp) once-daily (OD) versus insulin glargine (IGlar) U100 OD + insulin aspart (IAsp) OD for HbA(1c) after 26 weeks, and compare efficacy and safety between groups at W26 + W38.